PATTERNS AND PREVALENCE OF IMMUNE-RELATED ADVERSE EVENTS AS DETECTED WITH FDG PET/CT IN PATIENTS TREATED WITH COMBINED CTLA-4 AND PD-1 INHIBITOR AS FIRST-LINE THERAPY FOR ADVANCED MELANOMA